Novo Wins Dutch Injunction Against Compounded Semaglutide Spray

Novo Nordisk has obtained a preliminary injunction from the District Court of The Hague against Ceban Ziekenhuisfarmacie B.V., ordering the immediate cessation of sales of a compounded semaglutide nasal spray that infringed the company's supplementary protection certificate covering semaglutide.

The court found that Ceban violated Novo's intellectual property rights and ordered removal of the product from listings and websites, disclosure of supply chain information, and reimbursement of legal costs. No regulatory authority has approved a semaglutide nasal spray formulation.

The ruling reinforces Novo Nordisk's enforcement strategy against unapproved compounded GLP-1 products, which bypass EMA, FDA, and equivalent agency review for safety, efficacy, and manufacturing consistency.

Daily News
Regend Launches First Phase III Cell Therapy Study in COPD
2026-09-21
Ultragenyx Places First Therapy for Sanfilippo Syndrome Type A in US
2026-09-21
Nutshell's Covalent NRF2 Molecular-Glue Degrader Clears IND in US
2026-09-18
Sanofi Opens Upgraded Shanghai R&D Innovation Centre
2026-09-18
Arrowhead RNAi Shows Dual Silencing in Mixed Hyperlipidaemia
2026-09-17
Latest Report
2026 TOP-25 Drug Targets
Details